


This listing of claims will replace all prior versions, and listings, of claims in the application.

*Listing of Claims*

1. *(currently amended)* A compound of formula I:



wherein

R<sup>1</sup> is hydroxy, halo, cyano, carboxamido, carboalkoxy of 2 to 6 carbon atoms, trifluoromethyl, alkyl of 1 to 6 carbon atoms, alkanoyloxy of 2 to 6 carbon atoms, amino, mono- or di-alkylamino in which each alkyl group has 1 to 6 carbon atoms, alkanamido of 2 to 6 carbon atoms, or alkanesulfonamido of 1 to 6 carbon atoms;

the group X—Y is —N=C(R<sup>2</sup>)-C(R<sup>3</sup>)=N-, —N=C(R<sup>2</sup>)-C(R<sup>4</sup>)=CH-, —N=C(R<sup>2</sup>)-N=CH-, —N=C(R<sup>2</sup>)-O-, or —NH-C(R<sup>5</sup>)=CH-;

R<sup>2</sup> and R<sup>3</sup> are, independently, hydrogen, halo, amino, mono- or di-alkylamino in which each alkyl group has 1 to 6 carbon atoms or alkyl of 1 to 6 carbon atoms;

R<sup>4</sup> is hydrogen or alkyl of 1 to 6 carbon atoms;

R<sup>5</sup> is hydrogen, halo, trifluoromethyl, pentafluoroethyl or alkyl of 1 to 6 carbon atoms;

Ar is phenyl, naphthyl, indolyl, indazolyl, thienyl, pyridinyl, pyrimidinyl, quinolinyl, benzofuranyl, benzothienyl, benzoisothiazolyl, or benzisoxazolyl, each optionally substituted with one to three substituents independently selected from hydroxy, halo, cyano, carboxamido, carboalkoxy of 2 to 6 carbon atoms, trifluoromethyl, alkyl of 1 to 6 carbon atoms, alkanoyloxy of 2 to 6 carbon atoms, amino, mono- or di-alkylamino in which each alkyl group has 1 to 6 carbon atoms, alkanamido of 2 to 6 carbon atoms, or alkanesulfonamido of 1 to 6 carbon atoms; and

n is 1 or 2;

**or pharmaceutically acceptable salts thereof.**

2. *(original)* A compound according to claim 1, wherein R<sup>1</sup> is hydrogen, halo, cyano, trifluoromethyl, alkyl of 1 to 6 carbon atoms or alkoxy of 1 to 6 carbon atoms.
3. *(original)* A compound according to claim 1, wherein R<sup>1</sup> is hydrogen, halo or alkoxy of 1 to 6 carbon atoms.
4. *(original)* A compound according to claim 1, wherein R<sup>1</sup> is hydrogen.
5. *(original)* A compound according to claim 1, wherein Ar is phenyl, quinoliny, benzofuranyl, benzothienyl, or indolyl, each optionally substituted.
6. *(original)* A compound according to claim 1, wherein X-Y is -N=C(R<sup>2</sup>)-C(R<sup>4</sup>)=CH- and R<sup>4</sup> is hydrogen or alkyl of 1 to 3 carbon atoms.
7. *(original)* A compound according to claim 1, wherein R<sup>2</sup> and R<sup>3</sup> when present are independently selected from hydrogen, amino or alkyl of 1 to 6 carbon atoms.
8. *(original)* A compound according to claim 1, wherein R<sup>2</sup> and R<sup>3</sup> when present are independently hydrogen or alkyl of 1 to 3 carbon atoms.
9. *(original)* A compound according to claim 1, wherein R<sup>5</sup> is hydrogen, trifluoromethyl, pentafluoroethyl or alkyl of 1 to 6 carbon atoms.
10. *(original)* A compound according to claim 1, wherein R<sup>5</sup> is hydrogen, trifluoromethyl or alkyl of 1 to 3 carbon atoms.
11. *(original)* A compound according to claim 1, wherein said compound is (2S)-2-{{4-(3-chlorophenyl)piperazin-1-yl}methyl}-8-methyl-2,3-dihydro[1,4]dioxino[2,3-f]quinoline or a pharmaceutically acceptable salt thereof.

12. *(original)* A compound according to claim 1, wherein said compound is (2S)-2-{{4-(4-chlorophenyl)piperazin-1-yl}methyl}-8-methyl-2,3-dihydro[1,4]dioxino[2,3-f]quinoline or a pharmaceutically acceptable salt thereof.
13. *(previously presented)* A compound according to claim 1, wherein said compound is (2S)-2-{{4-(3,4-dichlorophenyl)piperazin-1-yl}methyl}-8-methyl-2,3-dihydro[1,4]dioxine [2,3-f]quinoline or a pharmaceutically acceptable salt thereof.
14. *(original)* A compound according to claim 1, wherein said compound is (2S)-2-{{4-(2-methoxyphenyl)piperazin-1-yl}methyl}-8-methyl-2,3-dihydro[1,4]dioxino[2,3-f]quinoline or a pharmaceutically acceptable salt thereof.
15. *(original)* A compound according to claim 1, wherein said compound is (2S)-2-{{4-(3-methoxyphenyl)piperazin-1-yl}methyl}-8-methyl-2,3-dihydro[1,4]dioxino[2,3-f]quinoline or a pharmaceutically acceptable salt thereof.
16. *(original)* A compound according to claim 1, wherein said compound is (2S)-2-{{4-(4-methoxyphenyl)piperazin-1-yl}methyl}-8-methyl-2,3-dihydro[1,4]dioxino[2,3-f]quinoline or a pharmaceutically acceptable salt thereof.
17. *(previously presented)* A compound wherein said compound is (2S)-2-{{4-(dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl}methyl}-8-methyl-2,3-dihydro[1,4]dioxino[2,3-f]quinoline or a pharmaceutically acceptable salt thereof.
18. *(previously presented)* A compound according to claim 1, wherein said compound is (2S)-8-methyl-2-[4-(3-trifluoromethyl-phenyl)piperazin-1-ylmethyl]-2,3-dihydro[1,4]dioxino[2,3-f]quinoline or a pharmaceutically acceptable salt thereof.
19. *(previously presented)* A compound according to claim 1, wherein said compound is (2S)-8-methyl-2-[4-(3-fluorophenyl)piperazin-1-ylmethyl]-2,3-dihydro[1,4]dioxino[2,3-f]quinoline or a pharmaceutically acceptable salt thereof.

20. *(original)* A compound according to claim 1, wherein said compound is (2S)-2-{{4-(2,3-dimethylphenyl)piperazin-1-yl}methyl}-8-methyl-2,3-dihydro[1,4]dioxino[2,3-f]quinoline or a pharmaceutically acceptable salt thereof.
21. *(original)* A compound according to claim 1, wherein said compound is (2S)-2-{{4-(3,4-dimethylphenyl)piperazin-1-yl}methyl}-8-methyl-2,3-dihydro[1,4]dioxino[2,3-f]quinoline or a pharmaceutically acceptable salt thereof.
22. *(original)* A compound according to claim 1, wherein said compound is (2S)-8-methyl-2-[(4-quinolin-2-yl)piperazin-1-yl]methyl-2,3-dihydro[1,4]dioxino[2,3-f]quinoline or a pharmaceutically acceptable salt thereof.
23. *(original)* A compound according to claim 1, wherein said compound is ((2S)-8-methyl-2-{4-(6-nitroquinolin-2-yl)piperazin-1-yl}methyl)-2,3-dihydro[1,4]dioxino[2,3-f]quinoline or a pharmaceutically acceptable salt thereof.
24. *(original)* A compound according to claim 1, wherein said compound is (2S)-8-methyl-2-{4-(6-chloroquinolin-2-yl)piperazin-1-yl}methyl-2,3-dihydro[1,4]dioxino[2,3-f]quinoline or a pharmaceutically acceptable salt thereof.
25. *(original)* A compound according to claim 1, wherein said compound is 2-(4-{{(2S)-8-methyl-2,3-dihydro[1,4]dioxino[2,3-f]quinolin-2-yl}methyl}piperazin-1-yl}quinoline-6-carbonitrile or a pharmaceutically acceptable salt thereof.
26. *(original)* A compound according to claim 1, wherein said compound is (2S)-2-{{4-(1-benzofuran-3-yl)-1-piperazinyl}methyl}-8-methyl-2,3-dihydro[1,4]dioxino[2,3-f]quinoline or a pharmaceutically acceptable salt thereof.

27. *(original)* A compound according to claim 1, wherein said compound is (2S)-2-{[4-(5-fluoro-1-benzofuran-3-yl)-1-piperazinyl]methyl}-8-methyl-2,3-dihydro[1,4]dioxino[2,3-f]quinoline or a pharmaceutically acceptable salt thereof.
  
28. *(original)* A compound according to claim 1, wherein said compound is ((2S)-2-{[4-(7-methoxy-1-benzofuran-3-yl)-1-piperazinyl]methyl}-8-methyl-2,3-dihydro[1,4]dioxino[2,3-f]quinoline or a pharmaceutically acceptable salt thereof.
  
29. *(original)* A compound according to claim 1, wherein said compound is (2S)-8-methyl-2-{[(2S)-2-methyl-4-quinolin-2-ylpiperazin-1-yl]methyl}-2,3-dihydro[1,4]dioxino[2,3-f]quinoline or a pharmaceutically acceptable salt thereof.
  
30. *(original)* A compound according to claim 1, wherein said compound is 2-((3R)-3-methyl-4-{[(2S))-8-methyl-2,3-dihydro[1,4]dioxino[2,3-f]quinolin-2-yl]methyl}piperazin-1-yl]quinoline-6-carbonitrile or a pharmaceutically acceptable salt thereof.
  
31. *(original)* A compound according to claim 1, wherein said compound is (2S)-8-methyl-2-{[(2R)-2-methyl-4-quinolin-2-ylpiperazin-1-yl]methyl}-2,3-dihydro[1,4]dioxino[2,3-f]quinoline or a pharmaceutically acceptable salt thereof.
  
32. *(original)* A compound according to claim 1, wherein said compound is (2S)-8-methyl-2-{[4-(2-naphthyl)piperazin-1-yl]methyl}-2,3-dihydro[1,4]dioxino[2,3-f]quinoline or a pharmaceutically acceptable salt thereof.
  
33. *(original)* A compound according to claim 1, wherein said compound is (2S)-2-[4-8-methyl-2,3-dihydro-[1,4]dioxino[2,3-f]quinolin-2-yl)-piperazin-1-yl]-quinoline-6-carboxylic acid amide or a pharmaceutically acceptable salt thereof.

34. *(original)* A compound according to claim 1, wherein said compound is (2S)-2-[4-(2,3-Dihydro-[1,4]dioxino[2,3-f]quinolin-2-ylmethyl)-piperazin-1-yl]-quinoline-6-carbonitrile or a pharmaceutically acceptable salt thereof.
35. *(original)* A compound according to claim 1, wherein said compound is (2S)-2-[4-(8-Ethyl-2,3-dihydro-[1,4]dioxino[2,3-f]quinolin-2-ylmethyl)-piperazin-1-yl]-quinoline-6-carbonitrile or a pharmaceutically acceptable salt thereof.
36. *(original)* A compound according to claim 1, wherein said compound is (2S)-2-[4-(2-Methyl-7,8-dihydro-1,6,9-trioxa-3-aza-cyclopenta[a]naphthalen-8-ylmethyl)-piperazin-1-yl]-quinoline-6-carbonitrile or a pharmaceutically acceptable salt thereof.
37. *(original)* A compound according to claim 1, wherein said compound is (2S)-2-{[4-(6-Bromoquinolin-2-yl)piperazin-1-yl]methyl}-8-methyl-2,3-dihydro[1,4]dioxino[2,3-f]quinoline or a pharmaceutically acceptable salt thereof.
38. *(original)* A compound according to claim 1, wherein said compound is (2S)-2-{[4-(6-Bromoquinolin-2-yl)piperazin-1-yl]methyl}-8-methyl-2,3-dihydro[1,4]dioxino[2,3-f]quinoline or a pharmaceutically acceptable salt thereof.
39. *(original)* A compound according to claim 1, wherein said compound is (2S)-2-{[4-(6-methoxyquinolin-2-yl)piperazin-1-yl]methyl}-8-methyl-2,3-dihydro[1,4]dioxino[2,3-f]quinoline or a pharmaceutically acceptable salt thereof.
40. *(original)* A compound according to claim 1, wherein said compound is (2S)-2-{[4-(6-Trifluoromethoxyquinolin-2-yl)piperazin-1-yl]methyl}-8-methyl-2,3-dihydro[1,4]dioxino[2,3-f]quinoline or a pharmaceutically acceptable salt thereof.
41. *(original)* A compound according to claim 1, wherein said compound is 2-[4-(6-Fluoroquinolin-2-yl)-piperazin-1-ylmethyl]-8-methyl-2,3-dihydro-[1,4]dioxino[2,3-f]quinoline or a pharmaceutically acceptable salt thereof.

42. *(original)* A compound according to claim 1, wherein said compound is (2S)-2-{{4-(6-methoxyquinolin-2-yl)-1,4-diazepan-1-yl)methyl}-8-methyl-2,3-dihydro[1,4]dioxino[2,3-f]quinoline or a pharmaceutically acceptable salt thereof.
43. *(original)* A compound according to claim 1, wherein said compound is 2-(4-{{(2S)-8-Methyl-2,3-dihydro[1,4]dioxino[2,3-f]quinolin-2-yl)methyl}-1,4-diazepan-1-yl)quinoline-6-carbonitrile or a pharmaceutically acceptable salt thereof.
44. *(original)* A compound according to claim 1, wherein said compound is (2S)-2-{{4-(6-Trifluoromethoxy-quinolin-2-yl)-1,4-diazepan-1-yl)methyl}-8-methyl-2,3-dihydro[1,4]dioxino[2,3-f]quinoline or a pharmaceutically acceptable salt thereof.
45. *(original)* A compound according to claim 1, wherein said compound is 2-[4-(6-Fluoro-quinolin-2-yl)-[1,4]diazepan-1-ylmethyl]-8-methyl-2,3-dihydro-[1,4]dioxino[2,3-f]quinoline or a pharmaceutically acceptable salt thereof.
46. *(original)* A compound according to claim 1, wherein said compound is (2S)-2-{{4-(6-Bromo-quinolin-2-yl)-1,4-diazepan-1-yl)methyl}-8-methyl-2,3-dihydro[1,4]dioxino[2,3-f]quinoline or a pharmaceutically acceptable salt thereof.
47. *(original)* A compound according to claim 1, wherein said compound is 8-Methyl-2-(4-quinolin-2-yl-[1,4]diazepan-1-ylmethyl)-2,3-dihydro-[1,4]dioxino[2,3-f]quinoline or a pharmaceutically acceptable salt thereof.
48. *(previously presented)* A compound according to claim 1, wherein said compound is 8-Methyl-2-[4-(4-methyl-quinolin-2-yl)-[1,4]diazepan-1-ylmethyl]-2,3-dihydro[1,4]dioxino[2,3-f]quinoline or a pharmaceutically acceptable salt thereof.
49. *(original)* A method of treating a subject suffering from a condition selected from depression, anxiety, panic disorder, post-traumatic stress disorder, premenstrual

dysphoric disorder, attention deficit disorder, obsessive-compulsive disorder, social anxiety disorder, generalized anxiety disorder, obesity, eating disorders, vasomotor flushing, alcohol addiction, and sexual dysfunction, comprising the step of:

providing to said subject suffering from said condition, a therapeutically effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof.

50. *(original)* A method according to claim 49, wherein the condition is depression.

51. *(original)* A method according to claim 49, wherein the condition is selected from the group consisting of obsessive-compulsive disorder, panic attacks, generalized anxiety disorder, and social anxiety disorder.

52. *(original)* A pharmaceutical composition, comprising:

an effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof; and  
a pharmaceutically acceptable carrier or excipient.